The company’s portfolio contains small molecules with potential indications including anti-inflammation, nerve generation and cardiovascular disease. Their vision is to lead the development of new molecules with agonistic action to the AT2 receptor into successful clinical drug entities. The AT2 receptor is expressed and activated in the fetus where it supports organ development and differention, and in damaged adult tissue where it restitutes morphology and function, restores heart function after myocardial infarction, reduces inflammation, regenerates neural tissue – to mention but a few of the beneficial effects.
- Bli medlem
- Om SwedenBIO